Clinical Research Directory

Inclusion Criteria: * Age: ≥ 18 years * Diagnosis: Hodgkin lymphoma or non-Hodgkin lymphoma * Disease status: complete response, partial response, or stable disease after at least 2 cycles of treatment (see appendix 2 for definition) * Planned to receive ESHAP (etoposide, steroid, high-dose cytarabine, cisplatin) chemotherapy with/without monoclonal antibody (ex: rituximab, brentuximab) as chemo-mobilization for stem cell harvest * East-Asian heritage Exclusion Criteria: * History of vascular thromboembolic event * Steady state platelet count \> 1000k/μL * Documented cytogenetic abnormalities in marrow blood * Current administration of eltrombopag * History of grade III-IV hepatotoxicity to eltrombopag 75/mg/day * Life-threatening allergic reactions to eltrombopag * Baseline serum aspartate aminotransferase (AST), alanine aminotransferase(ALT) or total bilirubin \> 3 fold of upper limit of normal * Pregnancy or breast-feeding * Patients with hepatitis C receiving interferon and ribavirin treatment * Concurrent active cancer other than lymphoma * Eastern Cooperative Oncology Group (ECOG) 3-4 (see appendix 4 for definition) * Moribund status such as concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious disease that death within 30 days is likely. * Inability to understand the investigational nature of the study or to give informed consent